Efficacy of Immunohistochemistry for SDHB in the Screening of Hereditary Pheochromocytoma-Paraganglioma

被引:5
作者
Choi, Hye-Ryeon [1 ]
Koo, Ja-Seung [2 ]
Lee, Cho-Rok [3 ]
Lee, Jan-Dee [3 ]
Kang, Sang-Wook [3 ]
Jo, Young-Seok [4 ]
Chung, Woong-Youn [3 ]
机构
[1] Eulji Univ, Eulji Med Ctr, Dept Surg, Sch Med, Seoul 01830, South Korea
[2] Yonsei Univ, Dept Pathol, Coll Med, Seoul 03722, South Korea
[3] Yonsei Univ, Dept Surg, Coll Med, Seoul 03722, South Korea
[4] Yonsei Univ, Dept Internal Med, Coll Med, Seoul 03722, South Korea
来源
BIOLOGY-BASEL | 2021年 / 10卷 / 07期
关键词
pheochromocytoma; sympathetic paraganglioma; genetic screening; immunohistochemistry; SDHB; ADRENAL-TUMORS; MUTATIONS; HYPOXIA; HEAD;
D O I
10.3390/biology10070677
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Simple Summary The majority of hereditary pheochromocytoma and paraganglioma (PPGL) is caused by germline mutations in the SDHB, SDHC, or SDHD genes, which encode three (SDHB, SDHC, SDHD) of five subunits of succinate dehydrogenase (SDH) enzyme (SDHA, SDHDB, SDHC, SDHD, SDHAF2). The inactivation of any of the SDHx genes leads to the proteolysis of SDH. This can be detected with negative immunohistochemistry (IHC) for SDHB. However, there is no consensus of the interpretation of "weakly positive" staining. Hence, we carried out a retrospective single centre study comprising 58 patients to evaluate the efficacy of using SDHB IHC for detecting SDHx mutation in PPGL cases. Our analyses revealed that SDHB-negative IHC is a cost-effective and reliable method to predict SDHx mutations in the Korean population. Nonetheless, in the case of weakly positive staining, an additional gene study should be considered. The most common genetic backgrounds of hereditary paraganglioma and pheochromocytoma (PPGL) are SDHx germline mutations. Given the fact that the immunohistochemistry (IHC) result for SDHB is always negative regardless of the type of SDHx mutation, we aimed to evaluate the efficacy of using SDHB IHC for screening SDHx mutations in PPGL cases. In total, 52 patients who underwent surgery for PPGL treatment between 2006 and 2020 and underwent genetic analysis at diagnosis were included. Tissue microarrays (TMAs) were constructed with PPGL tissues and IHC for SDHB was performed on TMA sections. All 10 patients with SDHB-negative IHC contained SDHB or SDHD mutations. The genetic test results of patients with SDHB-weakly positive IHC varied (one SDHB, two RET, one VHL, and three unknown gene mutations). There were no SDHx mutations in the SDHB-positive IHC group. Six patients with weakly positive SDHB IHC with primarily unknown genetic status were re-called and underwent next-generation sequencing. None of them had SDHx mutations. In conclusion, SDHB-negative IHC is a cost-effective and reliable method to predict SDHx mutations. However, in the case of weakly positive SDHB staining, an additional gene study should be considered.
引用
收藏
页数:9
相关论文
共 29 条
[1]   Genetic testing in pheochromocytoma or functional paraganglioma [J].
Amar, L ;
Bertherat, J ;
Baudin, E ;
Ajzenberg, C ;
Bressac-de Paillerets, B ;
Chabre, O ;
Chamontin, B ;
Delemer, B ;
Giraud, S ;
Murat, A ;
Niccoli-Sire, P ;
Richard, SP ;
Rohmer, V ;
Sadoul, JL ;
Strompf, L ;
Schlumberger, M ;
Bertagna, X ;
Plouin, PF ;
Jeunemaitre, X ;
Gimenez-Roqueplo, AP .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (34) :8812-8818
[2]   Clinical and genetic characteristics of patients with neurofibromatosis type 1 and pheochromocytoma [J].
Bausch, Birke ;
Borozdin, Wiktor ;
Neumann, Hartmut P. H. .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (25) :2729-2731
[3]   Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes [J].
Benn, DE ;
Gimenez-Roqueplo, AP ;
Reilly, JR ;
Bertherat, J ;
Burgess, J ;
Byth, K ;
Croxson, M ;
Dahia, PLM ;
Elston, M ;
Gimm, O ;
Henley, D ;
Herman, P ;
Murday, V ;
Niccoli-Sire, P ;
Pasieka, JL ;
Rohmer, V ;
Tucker, K ;
Jeunemaitre, X ;
Marsh, DJ ;
Plouin, PF ;
Robinson, BG .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (03) :827-836
[4]   SDHB loss predicts malignancy in pheochromocytomas/sympathethic paragangliomas, but not through hypoxia signalling [J].
Blank, Annika ;
Schmitt, Anja M. ;
Korpershoek, Esther ;
van Nederveen, Francien ;
Rudolph, Thomas ;
Weber, Nicole ;
Strebel, Raeto Thomas ;
de Krijger, Ronald ;
Komminoth, Paul ;
Perren, Aurel .
ENDOCRINE-RELATED CANCER, 2010, 17 (04) :919-928
[5]   Usefulness of Negative and Weak-Diffuse Pattern of SDHB Immunostaining in Assessment of SDH Mutations in Paragangliomas and Pheochromocytomas [J].
Castelblanco, Esmeralda ;
Santacana, Maria ;
Valls, Joan ;
de Cubas, Aguirre ;
Cascon, Alberto ;
Robledo, Mercedes ;
Matias-Guiu, Xavier .
ENDOCRINE PATHOLOGY, 2013, 24 (04) :199-205
[6]   Pheochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity [J].
Dahia, Patricia L. M. .
NATURE REVIEWS CANCER, 2014, 14 (02) :108-119
[7]   A HIF1α regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas [J].
Dahia, PLM ;
Ross, KN ;
Wright, ME ;
Hayashida, CY ;
Santagata, S ;
Barontini, M ;
Kung, AL ;
Sanso, G ;
Powers, JF ;
Tischler, AS ;
Hodin, R ;
Heitritter, S ;
Moore, F ;
Dluhy, R ;
Sosa, JA ;
Ocal, IT ;
Benn, DE ;
Marsh, DJ ;
Robinson, BG ;
Schneider, K ;
Garber, J ;
Arum, SM ;
Korbonits, M ;
Grossman, A ;
Pigny, P ;
Toledo, SPA ;
Nosé, V ;
Li, C ;
Stiles, CD .
PLOS GENETICS, 2005, 1 (01) :72-80
[8]   SDHD mutations in head and neck paragangliomas result in destabilization of complex II in the mitochondrial respiratory chain with loss of enzymatic activity and abnormal mitochondrial morphology [J].
Dekker, PBD ;
Hogendoorn, PCW ;
Kuipers-Dijkshoorn, N ;
Prins, FA ;
van Duinen, SG ;
Taschner, PEM ;
van der Mey, AGL ;
Cornelisse, CJ .
JOURNAL OF PATHOLOGY, 2003, 201 (03) :480-486
[9]  
Eisenhofer Graeme, 2017, Clin Biochem Rev, V38, P69
[10]   Succinate dehydrogenase (SDH)-deficient neoplasia [J].
Gill, Anthony J. .
HISTOPATHOLOGY, 2018, 72 (01) :106-116